Amgen (AMGN) Research & Development (2009 - 2026)

Amgen has reported Research & Development for 18 years, with the latest figure at $1.9 billion in Q2 2026.

• On a quarterly basis, Research & Development rose 7.11% year-over-year to $1.9 billion in Q2 2026; TTM through Jun 2026 was $7.6 billion, a 19.13% increase from a year earlier, with the FY2025 full-year figure at $7.3 billion, up 21.93% from the prior year.
• Research & Development was $1.9 billion for Q2 2026 at Amgen, up from $1.7 billion in the prior quarter.
• The five-year high for Research & Development was $2.1 billion in Q4 2025, with the low at $959.0 million in Q1 2022.
• Average Research & Development over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Research & Development slipped 21.8% in 2022, then soared 34.38% in 2024.
• Over 5 years, Research & Development stood at $1.3 billion in 2022, then grew by 15.86% to $1.5 billion in 2023, then grew by 12.39% to $1.7 billion in 2024, then rose by 24.25% to $2.1 billion in 2025, then declined by 12.79% to $1.9 billion in 2026.
• The last three Research & Development figures came in at $1.9 billion (Q2 2026), $1.7 billion (Q1 2026), and $2.1 billion (Q4 2025), per Business Quant data.